AstraZeneca Confident About Evusheld's Future Growth
As Next-Generation Version Moves Towards Clinic
Now approved for the treatment as well as the prevention of COVID-19 in the EU and Japan, the UK major’s antibody combo passed the $500m sales barrier in the third quarter and CEO Pascal Soriot is confident that growth will continue.
